Etiology and response to drug treatment in heart failure

Journal of the American College of Cardiology

Volumn 32, Issue 5, 1998, Pages 1167-1172

  Follath, Ferenc ^a   Cleland, John G F ^b   Klein, Werner ^c   Murphy, Richard ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

^d University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARDIAC GLYCOSIDE; CARVEDILOL; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; METOPROLOL; NEUROHORMONE; PLACEBO;

CLINICAL TRIAL; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0032212274     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00400-8     Document Type: Article

References (71)

1. Franciosa J. Epidemiologic patterns, clinical evaluation, and long-term prognosis in chronic congestive heart failure. Am J Med 1986;80 Suppl 2B:14-21.
2. Eriksson H. How common and how much of a problem is heart failure? In: McMurray JJV, Cleland JGF, editors. Heart Failure in Clinical Practice. London: Martin Dunitz Ltd, 1996:29-38.
3. Poole-Wilson PA. What are we trying to achieve when we treat heart failure? In: McMurray JJV, Cleland JGF, editors. Heart Failure in Clinical Practice. London: Martin Dunitz Ltd, 1996:73-82.
4. Codd MB, Surge DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989;80:564-72.
5. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
6. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
7. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
8. Goerss JB, Michels VV, Burnett J, et al. The frequency of familial dilated cardiomyopathy. Eur Heart J 1995;16 Suppl:2-4.
9. Goldman JH, Keeling PJ, Warraich RS, et al. Autoimmunity to a myosin in a subset of patients with idiopathic dilated cardiomyopathy. Heart 1995;74:598-603.
10. Limas CJ, Limas C, Kubo SH, Olivari MT. Anti-beta-receptor antibodies in human dilated cardiomyopathy and correlation with HLA-DR antigens. Am J Cardiol 1990;65:483.
11. 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990;86:1658.
12. 1-adrenoceptor with positive chronotropic effect. Circulation 1994;89:2760.
13. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996;347:1151-5.
14. Matsumori A, Shohi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-8.
15. Kroncke K-D, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Biol Chem Hoppe Seyler 1995;376:327-43.
16. Packer M. The neurohormonal hypothesis; a theory to explain the mechanisms of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
17. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
18. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
19. Singh N, Dhalla AK, Seneviratne C, Singal PK. Oxidative stress and heart failure. Mol Cell Biochem 1995;147:77-81.
20. Belch JJF, Budges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Heart J 1991;65:245-8.
21. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ. Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biol Med 1993;14:643-7.
22. Chesebro JH, Fuster V, Webster MWI. Endothelial injury and coronary vasomotion (editorial). J Am Coll Cardiol 1989;14:1191.
23. Braunwald E, Sobel BE. Coronary blood flow and myocardial ischemia. In: Braunwald E, editor. Heart Disease: a Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: W. B. Saunders Company, 1992:1161-99.
24. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:722-9.
25. Wynne J, Braunwald E. The cardiomyopathies and myocarditides: toxic, chemical, and physical damage to the heart. In: Braunwald E, editor. Heart Disease: a Textbook of Cardiovascular Medicine. 4th ed. Philadelphia: W. B. Saunders Company, 1992:1394-450.
26. Iskandrian AS, Hakki AH, Kane S. Resting thallium-201 myocardial perfusion patterns in patients with severe left ventricular dysfunction: differences between patients with primary cardiomyopathy, chronic coronary artery disease, or acute myocardial infarction. Am Heart J 1986;11:760-7.
27. Rahko PS, Orie JE. The clinical presentation and laboratory evaluation of congestive and ischemic cardiomyopathies. Cardiovasc Clin 1988;19:75-119.
28. Uretsky BF. Diagnostic considerations in the adult patient with cardiomyopathy or congestive heart failure. Cardiovasc Clin 1988;19:35-56.
29. Mody FV, Brunken RC, Stevenson LW, Nienaber CA, Phelps ME, Schelbert HR. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography. J Am Coll Cardiol 1991;17:373-83.
30. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983;51:831-6.
31. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996;28:1781-8.
32. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 1997;59:634-8.
33. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction ≤20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990;60:1348-54.
34. Levine TB, Levine AB, Goldberg D, Narins B, Goldstein S, Lesch M. Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation. Am J Cardiol 1986;78:440-3.
35. Cohn J, Aichibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547-52.
36. Packer M, Carver R, Rodeheffer Jr, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
37. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-56.
38. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study. Circulation 1994;90:1765-73.
39. Packer M, Bristow MR, Cohn JN, et al., for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
40. Packer M, O'Connor CM, Ghali JK, et al., for the PRAISE Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
41. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
42. Keeling PJ, Goldman JH, Slade AKB, et al. Prognosis of idiopathic dilated cardiomyopathy. J Cardiac Failure 1995;1:337-45.
43. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22:6A-13A.
44. Adams KF Jr, Georghiade M, Uretsky BF, et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol 1997;30:42-8.
45. Anand IS. Digitalis in the 21st century. In: McMurray JJV, Cleland JGF, editors. Heart Failure in Clinical Practice. London: Martin Dunitz Ltd, 1996:237-55.
46. Digitalis Investigators Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
47. Nony P, Boissel JP, Girard P, Leizorovicz A, Lievre M, Chifflet R. Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure. Eur Heart J 1992;13:1101-8.
48. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
49. Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in hart failure. Should they be used and how? Eur Heart J 1996;17:1629-39.
50. CIBIS II Scientific Committee. Design of the cardiac insufficiency bisoprolol study II. Fundam Clin Pharmacol 1997;11:138-42.
51. 50a. Dargie HJ, for the CIBIS II investigators. The CIBIS II study. Presentation No. 771, XX Congress of the European Society of Cardiology, Vienna, Austria, 1998.
52. Colucci WS, Packer M, Bristow R, et al., for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
53. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in patients with chronic heart failure. Circulation 1996;94:2807-16.
54. Packer M, Collucci WS, Sackner-Bernstein JD, et al., for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation 1996;94:2793-9.
55. Cohn JN, Fowler MB, Bristow MA, et al. Safety and efficacy of carvedilol in severe chronic heart failure. J Cardiac Failure 1997;3:173-9.
56. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
57. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995;92:212-8.
58. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
59. Poole-Wilson P, Swedberg K, Remme WJ, et al. A multicentre randomised double-blind study to compare the effect on mortality and morbidity over 24-44 months of carvedilol and metoprolol in patients with moderate or severe congestive heart failure (NYHA II-IV) - COMET. In: European Society of Cardiology, editor. Heart Failure '97 Meeting. Cologne, 1997:41, Abstract P155.
60. Doval HC, Hul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe heart failure. Lancet 1994;344:493-8.
61. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
62. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN. Effects of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996;93:2128-34.
63. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S, Adverse Experience Committee, Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
64. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.
65. Figulla HR, et al. Diltiazem as adjunct treatment in idiopathic dilated cardiomyopathy. Results of the DiDi-trial. J Am Coll Cardiol 1996;27 Suppl A:141A (abstr).
66. Cohn JN, Ziesche SM, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT-III. Circulation 1997;96:856-63.
67. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Heart J 1995;73:428-33.
68. Poole-Wilson PA. Amlodipine in chronic heart failure (letter). N Engl J Med 1997;336:1023.
69. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
70. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-14.
71. Remme WJ, Harland D, Court M, for the CARMEN Investigators. CARMEN: Carvedilol ACE inhibitor Remodelling Mild heart failure EvaluatioN). In: European Society of Cardiology, editor. Heart Failure '97 Meeting. Cologne, 1997:41, Abstract P156.